NMO Spectrum Disorder
2
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
AstraZenecaCAMBRIDGE, United Kingdom
1 programAcceptance and Commitment TherapyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Jazz PharmaceuticalsNabiximols
BiomedHBM9161 Injection
AstraZenecaAcceptance and Commitment Therapy
Clinical Trials (3)
Total enrollment: 52 patients across 3 trials
A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders
Start: Dec 2026Est. completion: Sep 20270
Phase 2Withdrawn
A Study of HBM9161 in NMOSD Patients
Start: Mar 2020Est. completion: Dec 20219 patients
Phase 1Completed
ACT with NMOSD Patients and Caregivers Pilot Study
Start: Aug 2023Est. completion: Nov 202443 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.